Rolf Stahel教授：合作是突破研究瓶颈的关键
ESMO候任主席Rolf Stahel教授
丁香园：Dear Pro. Rolf Stahel, fist of all, thank you for this interview.Could you share some of your feelings for attending CSCO in Xiamen?（能否分享以下您参加本次CSCO大会的感受）
Pro. Rolf Stahel：I feel very proud to be here and I’m very glad to see science and coherence moving in the same way in my experience, to see a lot of similarity between doctors here in China and in Europe.
我非常荣幸受邀参加今年的CSCO 会议。非常高兴发现我们的科研都沿着相似的轨道运行，中国医生和欧洲医生的许多相似之处。
丁香园： We know the European Thoracic Oncology Platform (ETOP) is an excellent project,could you briefly introduce how did it come into being?（我们了解到ETOP时一个非常重要的合作项目，能否简单介绍下它是如何诞生的吗？）
Pro. Rolf Stahel：ETOP came into life by a group of colleagues who share the same vision. When you found your colleagues and you have the same vision,then you can achieve a lot. And the same thing I see in China is CTONG and all the trials you started in China is in the way of working together.
ETOP是由一群有共同想法的人共同创建的。当你发现身边的同事和你有相同的想法时，可以做成许多事情。中国的CTONG协作组也是这样的情况，大家以协作的方式开展临床试验研究。
丁香园： We know that your Lungscape project has some trial center, would you mind talking a little bit about it? （lungscape项目目前在中国有一些合作的研究中心，这方面具体的情况如何？）
Pro. Rolf Stahel：LOne of them is the Shanghai Chest Clinic. It takes part in our trial research and contributes a lot of data.
上海交通大学附属胸科医院是ETOP项目在中国的合作中心之一，他们参与其中并贡献许多宝贵的资料。
丁香园：In the next couple years, what’re the most promising targets in lung cancer in your opinion? Is there any research about them?（在您看来，肺癌领域未来几年最有前景的靶点会有哪些？目前有哪些这方面的研究？）
Pro. Rolf Stahel：It may be the most promising targets can be found with EGFR and out of RAS.I think HER2 to me will be the next promising target. There is a propose in Europe HER2 dynamic study and also propose in Shanghai Pulmonary Hospital. They are very similar and they wan to move these parallel clinical trials and share the data.
我认为目前最热门的靶点应该是EGFR 和RAS系列。我个人认为HER2将会是下一个有前景的靶点。在欧洲目前正在进行HER2的动态研究方案。上海肺科医院也有这方面的方案。他们非常类似，我们期待能够推进这些平行的研究并共享研究数据。
丁香园：Do you think is there any difference with lung cancer patents between China and Europe?（您认为中国和欧洲的肺癌患者有何不同?）
Pro. Rolf Stahel：I cant’t tell that. I just know the molecular comparison of some of the two parts’patients are different. But I think in the end the patient has the terrible disease are quite the same. He yearns for his life and family support. The key event of having a cancer is not different between China and Europe.
这个问题很难讲。我只知道双方的并而你在分子对比上会有些不同。但是我认为罹患严重疾病的病人有许多相同之处。他们渴望生命和家人的支持关爱。中国和欧洲的癌症患者并没有本质上的不同。
丁香园：As the elect-president of ESMO, how do you think about the future cooperation between CSCO and ESMO?（作为ESMO的主席，您如何看待CSCO和ESMO之间的合作？）
Pro. Rolf Stahel：The cooperation will be close between ESMO and CSCO. We have a very clear vision and we would like to proceed to discuss exchange of panel of the laboratory for the limited of time like several months. The young people will get more personal experience, the Chinese doctors in Europe and European in China. And we are talking about the summit between ESMO and CSCO, which will probably take place next year in China.
And you see cooperation is between people. And the more we try and meet each other,the better it will become. So I really hope that between China and Europe ,there can be more complete project that we can work together.
ESMO and CSCO之间的合作将会越来越密切。很明确地看到ESMO和CSCO未来合作的方向，希望明年将在中国举办的ESMO和CSCO交流合作峰会，能够为中欧肿瘤医生提供更多交流的机会。双方的青年学者可以通过短暂的交流获得更多的感受和经验。
交流及合作很重要的一部分就是人才的合作。关于双方的合作我们可以有更多的尝试，我们越好地满足彼此的需求，合作将会变得更好。非常期待中国和欧洲之间开展更多的协作项目。
丁香园：Would you like to share your expectation about Chinese doctors?（对中国的医生们，您有什么寄语和期待？）
Pro. Rolf Stahel：Chinese doctors, please give the best care to your patients while do not forget we should participate researches to improve the outcome for the future.
希望中国医生在给予患者最好的治疗和关怀的同时能够积极参加临床研究，为未来的临床治疗做出更大的贡献。
丁香园：Thank you for your precious time!（感谢您接受丁香园的采访。）